CoChat

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration

Open access

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Introduction: A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficacy and safety of nintedanib with or without pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) who experienced disease progression during previous pirfenidone therapy. Methods: In this randomized, open-label, selection design phase II trial, patients with IPF and a ≥5% relative decline in FVC within 6 months of the pirfenidone administration period were randomly assigned to nintedanib (switch group) or nintedanib plus pirfenidone (combination group). The primary endpoint was the incidence of a ≥5% relative decline in FVC or death during the first 6 months. Results: Only 7 patients were enrolled (4 in the switch group and 3 in the combination group). Although the switch group continued with nintedanib for 1 year or more, 2 patients (66.7%) in the combination group discontinued nintedanib within 6 months due to severe adverse events. Given the slow case registration and safety concerns in the combination group, the trial was terminated without extending the registration. The incidence of a ≥5% relative decline in FVC during the first 6 months was 50.0% in the switch group and 66.7% in the combination group. There were no deaths during the observation period. Conclusions: Clinical trials verifying the use of pirfenidone after disease progression in IPF may be difficult to enroll patients. Definitive conclusions on both safety and efficacy cannot be drawn from the results of this study alone. Trial registration: UMIN Clinical Trial Registry; registration number, UMIN000019436; date of first registration, 21/10/2015; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022471.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000029232

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Consort flow diagram.
Figure 1 Consort flow diagram.CC BY-NC · PubMed Central
Figure 2 Change in FVC. In both groups, nintedanib suppressed the decline in FVC compared with that during the administration period for pirfenidone. ∗ In case 5, a lung function test was performed at day 167 for the 6-month efficacy assessment. However, the patient developed acute exacerbation of IPF soon after and discontinued taking nintedanib at day 172 before the 6-month follow-up. ☆ In case 6, a lung function test was performed on the same day the patient discontinued taking nintedanib (day 167). FVC = forced vital capacity.
Figure 2 Change in FVC. In both groups, nintedanib suppressed the decline in FVC compared with that during the administration period for pirfenidone. ∗ In case 5, a lung function test was performed at day 167 for the 6-month efficacy assessment. However, the patient developed acute exacerbation of IPF soon after and discontinued taking nintedanib at day 172 before the 6-month follow-up. ☆ In case 6, a lung function test was performed on the same day the patient discontinued taking nintedanib (day 167). FVC = forced vital capacity.CC BY-NC · PubMed Central
Figure 3 Change in SGRQ score. ∗ In case 5, an SGRQ was performed on day 167 for the 6-month efficacy assessment. However, the patient developed acute exacerbation of IPF soon after and discontinued taking nintedanib on day 172 before the 6-month follow-up. ☆ In case 6, an SGRQ was performed on the same day the patient discontinued taking nintedanib (day 168).
Figure 3 Change in SGRQ score. ∗ In case 5, an SGRQ was performed on day 167 for the 6-month efficacy assessment. However, the patient developed acute exacerbation of IPF soon after and discontinued taking nintedanib on day 172 before the 6-month follow-up. ☆ In case 6, an SGRQ was performed on the same day the patient discontinued taking nintedanib (day 168).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 11

Metadata

Authors
Ikeda, S., Sekine, A., Baba, T., Kato, T., Katano, T., Tabata, E., Shintani, R., Yamakawa, H., Oda, T., Okuda, R., Kitamura, H., Iwasawa, T., Takemura, T., & Ogura, T.
Affiliations
  • Kanagawa Cardiovascular and Respiratory Center (JP)
  • Japanese Red Cross Medical Center (JP)
Corresponding author
Ikeda, Satoshi
Venue
Medicine
Published
2022-06-03
Volume
101
Issue
22
Pages
e29232
ISSN
  • 0025-7974 (ISSN-L)
  • 1536-5964
OpenAlex
W4281729540
Cited by
11
References
14
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 1
FWCI
1.29
Type
journal article
Language
en
Open access
Locations
  • Medicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, nintedanib, pirfenidone, disease progression, forced vital capacity decline, combination therapy, drug switching, antifibrotic agents, adverse events, trial termination
MeSH terms
Humans, Indoles, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. https://app.cochat.ai/papers/10.1097/md.0000000000029232
The paper
Ikeda, S., Sekine, A., Baba, T., Kato, T., Katano, T., Tabata, E., Shintani, R., Yamakawa, H., Oda, T., Okuda, R., Kitamura, H., Iwasawa, T., Takemura, T., & Ogura, T. (2022). Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. Medicine. https://doi.org/10.1097/md.0000000000029232

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.